Worries that tumor necrosis factor (TNF) inhibitors may exacerbate or even cause lung disease in patients with rheumatoid ...

SAN CARLOS, CA and FORT WORTH, TX / ACCESSWIRE / January 9, 2025 / CAGE Bio, Inc., a clinical-stage biotechnology company advancing innovative therapies for high incidence immuno-dermatological ...

SAN CARLOS, CA and FORT WORTH, TX / ACCESSWIRE / January 9, 2025 / CAGE Bio, Inc., a clinical-stage biotechnology company advancing innovative therapies for high incidence immuno-dermatological disord ...

SAN CARLOS, CA and FORT WORTH, TX / ACCESSWIRE / January 9, 2025 / CAGE Bio, Inc., a clinical-stage biotechnology company ...

For several years, investigators have been studying combinations that include ruxolitinib, sold as Jakafi, to treat ...

A blockbuster drug is a therapy that generates at least $1 billion in sales. Clarivate’s Drugs to Watch 2025 report includes ...

Explore Belatacept's role in organ transplant care, and market insights on immunosuppressants, JAK inhibitors, and dd-cfDNA ...

While the New Year's tradition of drug price hikes has held firm for years, pharma companies have decidedly tamped down on ...

There’s a balance required to manage both the symptoms of myelofibrosis through treatment and the side effects caused by the ...

In its pursuit of a cancer drug for pancreatic cancer and possibly ovarian cancer, Amplia has history on its side.

Pinnacle odds comparison Oral JAK inhibitor Filgotinib in the treatment of UC 2b/3 reached the primary endpoint The Lancet published a major ar ...

INR:4241. hemjeet kaur The fourth batch of national procurement provinces officially started reporting Zelgen Pharmaceuticals' JAK inhibitor receives FDA orphan drug ...